Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
This time around, NICE assessed the med using a faster cost comparison process that compared Lynparza to Pfizer’s Talzenna in benefits and cost. Stallergenes Greer’s peanut allergy treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback